70 related articles for article (PubMed ID: 9570362)
1. LDL-dependent regulation of Bcl-2 and cyclin 'D' gene expression in lymphocytes from normal and CML patients.
Kaul D; Kaur M
Cancer Lett; 1997 Nov; 119(2):131-5. PubMed ID: 9570362
[TBL] [Abstract][Full Text] [Related]
2. Receptor-Ck controls the expression of Bcl-2 and cyclin d genes.
Kaul D; Kaur M
Leuk Res; 1998 Aug; 22(8):671-5. PubMed ID: 9680093
[TBL] [Abstract][Full Text] [Related]
3. Receptor-Ck-dependent regulation of genes in HL-60 cell line.
Kaul D; Kaur M
Leuk Res; 1997; 21(11-12):1047-9. PubMed ID: 9444938
[TBL] [Abstract][Full Text] [Related]
4. Does receptor-'Ck' deficiency initiate leukaemia?
Kaul D; Singh J
Cancer Lett; 1997 Jan; 112(2):199-202. PubMed ID: 9066728
[TBL] [Abstract][Full Text] [Related]
5. Receptor-'Ck' dependent signalling regulates the LDL-receptor gene transcription.
Goel R; Singh J; Kaul D
Mol Cell Biochem; 1997 Apr; 169(1-2):79-83. PubMed ID: 9089634
[TBL] [Abstract][Full Text] [Related]
6. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
[TBL] [Abstract][Full Text] [Related]
7. Sterol dependent LDL-receptor gene transcription in lymphocytes from normal and CML patients.
Goel R; Varma S; Kaul D
Cancer Lett; 1996 Oct; 107(2):193-8. PubMed ID: 8947512
[TBL] [Abstract][Full Text] [Related]
8. Receptor-Ck-dependent regulation of genes involved in the cell cycle.
Kaur M; Kaul D; Sobti RC
Mol Cell Biochem; 1998 Apr; 181(1-2):137-42. PubMed ID: 9562250
[TBL] [Abstract][Full Text] [Related]
9. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
10. Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
Iolascon A; Della Ragione F; Giordani L; Serra A; Saglio G; Faienza MF
Haematologica; 1998 Sep; 83(9):771-7. PubMed ID: 9825572
[TBL] [Abstract][Full Text] [Related]
11. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
[TBL] [Abstract][Full Text] [Related]
12. [Cyclin D2 expression in chronic myelogenous leukemia].
Song JM; Xu D; Fan EJ; Xu SR; Li D; Zhao CH
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):103-5. PubMed ID: 14990053
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia.
José-Enériz ES; Román-Gómez J; Cordeu L; Ballestar E; Gárate L; Andreu EJ; Isidro I; Guruceaga E; Jiménez-Velasco A; Heiniger A; Torres A; Calasanz MJ; Esteller M; Gutiérrez NC; Rubio A; Pérez-Roger I; Agirre X; Prósper F
Br J Haematol; 2008 Aug; 142(4):571-82. PubMed ID: 18537972
[TBL] [Abstract][Full Text] [Related]
14. RNA-mediated regulation of Receptor-Ck gene in human platelets.
Singh J; Kaul D
Mol Cell Biochem; 1997 Aug; 173(1-2):189-92. PubMed ID: 9278271
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism.
Raimondo S; Saieva L; Corrado C; Fontana S; Flugy A; Rizzo A; De Leo G; Alessandro R
Cell Commun Signal; 2015 Feb; 13():8. PubMed ID: 25644060
[TBL] [Abstract][Full Text] [Related]
16. A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.
Xia DY; Liu L; Hao MW; Liu Q; Chen RA; Liang YM
Braz J Med Biol Res; 2014 Dec; 47(12):1096-101. PubMed ID: 25387678
[TBL] [Abstract][Full Text] [Related]
17. The molecular biology of chronic myeloid leukaemia.
Melo JV
Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
Dasmahapatra G; Yerram N; Dai Y; Dent P; Grant S
Clin Cancer Res; 2007 Jul; 13(14):4280-90. PubMed ID: 17634558
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
[TBL] [Abstract][Full Text] [Related]
20. Chronic myelogenous leukemia molecular signature.
Nowicki MO; Pawlowski P; Fischer T; Hess G; Pawlowski T; Skorski T
Oncogene; 2003 Jun; 22(25):3952-63. PubMed ID: 12813469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
